Form 4: Maze Therapeutics President Sells Shares
Insider Transaction (Form 4)
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., sold 16,141 shares of common stock on October 1, 2026 for $26.93 per share.
Summary
- Option exercise/conversion: acquired 16,141 Common Stock at $10.42 ($168,189) on October 1, 2026; holds 16,141 after (Direct).
- Open-market sale: disposed of 16,141 Common Stock at $26.93 ($434,743) on October 1, 2026 (Direct).
- Option exercise/conversion: disposed of 16,141 Stock Option (Right to Buy) on October 1, 2026; holds 144,521 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $434,743 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Harold Bernstein — Officer (President, R&D & CMO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 16,141 | $10 | $168.2K | 16,141 |
| 2026-10-01 | Open-market sale | Common Stock | 16,141 | $27 | $434.7K | 0 |
| 2026-10-01 | Option exercise/conversion | Stock Option (Right to Buy) | 16,141 | — | — | 144,521 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (16,141 shares) |
| 2026-10-01 | Open-market sale (16,141 shares) |
| 2026-10-01 | Option exercise/conversion (16,141 shares) |
Keywords
insider transaction, Form 4, MAZE, Maze Therapeutics, Inc., bearish, Harold Bernstein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.